Company News

Company News RAG-01

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

JIANGSU, China, April 26, 2024 — Ractigen Therapeutics, a leader in the development of small…

ractigenApril 26, 2024

Company News RAG-01

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…

ractigenApril 3, 2024

Company News

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

Suzhou, China – January 29, 2024 – Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the…

ractigenJanuary 29, 2024

Company News RAG-01

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

JIANGSU, China, Dec. 06, 2023 — Ractigen Therapeutics, a leader in the field of small…

ractigenDecember 6, 2023

Company News

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Findings support saRNA as a therapeutic strategy to compensate dystrophin’s function by upregulating UTRN expression…

ractigenNovember 2, 2023

Company News RAG-17

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s…

ractigenJune 10, 2023

Company News

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically…

ractigenJune 10, 2023

Company News RAG-17

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…

ractigenMarch 3, 2023

Company News Homepage News

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…

ractigenJanuary 27, 2022

Company News Homepage News

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…

ractigenFebruary 10, 2021

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

Join Us

CONTACT US

Follow Us